Congenital Hyperinsulinism Clinical Trials
28 clinical trials for Congenital Hyperinsulinism across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism — RECRUITING · PHASE2
- 18F-DOPA II - PET Imaging Optimization — RECRUITING · PHASE3
- Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma — RECRUITING · PHASE1
- Effect of purified fish oils in glucose regulation — COMPLETED · PHASE2
- Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism — COMPLETED · PHASE3
- A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE) — TERMINATED · PHASE2
- Continuous Glucose Monitoring Alerts, Accuracy, and Patient Outcomes in Adults With Inherited Metabolic Disorders — COMPLETED · NA
- HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) — ACTIVE_NOT_RECRUITING · PHASE2
- 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia — OTHER
- RZ358 Treatment for Congenital Hyperinsulinism — ACTIVE_NOT_RECRUITING · PHASE3
- An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism — COMPLETED · PHASE2
- Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism — COMPLETED · PHASE2
- Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy — COMPLETED · PHASE4
- A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism — COMPLETED · PHASE3
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-ARM STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF RZ358 IN PATIENTS WITH CONGENITAL
HYPERINSULINISM — COMPLETED · PHASE3
- Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism — COMPLETED · PHASE2
- Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia — COMPLETED · PHASE2
- Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia — TERMINATED
- 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety — COMPLETED · PHASE3
- Pasireotide in Hyperinsulinemic Hypoglycemia — WITHDRAWN · PHASE2
- Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia — TERMINATED
- Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia — TERMINATED · PHASE1
- Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity — COMPLETED · PHASE1
- CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism — COMPLETED · PHASE2
- GLP-1 Receptor Expression in CHI — OTHER
- Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism — COMPLETED · PHASE1
- A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism — COMPLETED · PHASE2
- Sandostatine® LP and Hyperinsulinism — COMPLETED · PHASE2
Refine this search